Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Unknown 3Active not recruiting 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 87Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Recurrence 16Burkitt Lymphoma 13Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Biphenotypic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 5Leukemia 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Carcinoma, Non-Small-Cell Lung 4Waldenstrom Macroglobulinemia 3Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nausea 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Brain Neoplasms 3Renal Insufficiency 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2

Interventions

nirogacestat 1Tissue Banks 1Lenalidomide 1Dexamethasone 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1Blood Cell Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Paraproteinemias × Dexamethasone × Clear all
NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡